Celonic AG and Leukocare AG have announced a collaboration to support biopharmaceutical companies developing increasingly complex biologics.
The collaboration brings together Celonic's expertise in cell line development, drug substance process development, intensified bioprocessing and GMP manufacturing with Leukocare's unique data science-driven approach to drug product development.
By combining complementary scientific capabilities, the companies will support selected client programmes involving complex biologics, including bispecific antibodies, multispecific antibodies, fusion proteins and high-concentration formulations.
Celonic AG is a Swiss-based, privately held biopharmaceutical CDMO offering cell line development, process development and optimisation, and clinical and commercial GMP manufacturing for advanced biologics.
Its CHOvolution GS CHO-K1 platform, supported by transposase-enabled integration, is designed for strong expression performance across standard mAbs and complex molecules such as bispecifics and multispecific constructs.
Celonic also applies intensified and perfusion bioprocessing strategies to improve productivity, product quality and manufacturing robustness for bispecifics, multi-domain constructs and high-concentration biologics.
Leukocare specialises in data science-driven drug product development for biologics and advanced therapeutic modalities by combining molecular modelling, predictive analytics, biostatistics, Design of Experiments and formulation expertise to improve developability, manufacturability and long-term stability.
Creating competitive advantages for clients developing complex molecules, bispecifics and high-concentration drug products
Through the collaboration, Celonic and Leukocare will support selected client programmes by aligning formulation strategy, molecular characteristics, manufacturability and process development from preclinical development through to commercialisation.
This integrated approach is intended to reduce technical risk and support stable, manufacturable, scalable and patient-friendly drug products.
“Our collaboration highlights the decisive role of formulation in enabling complex biologics to reach the clinic,” said Samanta Cimitan, CEO of Celonic AG.
“By combining Celonic’s CHO-based development, intensified and perfusion bioprocessing, and GMP manufacturing with Leukocare’s development expertise, we create measurable value for clients developing complex molecules, bispecifics, and high-concentration drug products.”
“As biologics become more sophisticated, formulation development must be predictive, data-driven and closely connected with process development,” said Michael Scholl, CEO of Leukocare AG.
“Our collaboration with Celonic helps clients make better development decisions earlier, mitigate technical risk, and accelerate progress toward robust, manufacturable drug products.”
About the Collaboration
Celonic AG and Leukocare AG collaborate on client programmes when integrated expertise in biologics development, drug product development and manufacturing can help to address the challenges associated with complex therapeutic modalities.
By combining complementary scientific capabilities, the companies aim to support clients throughout development while each organisation continues to operate independently and serve its respective global customer base.
